Preclinical profile of cabazitaxel

References

• No authors listed FDA approves treatment IND protocol for taxol Clin Pharm 1992 11 912 1361164
   PubMedGoogle Scholar
• Label and Approval History – Taxol [webpage on the Internet] Silver Spring US Food and Drug Administration 2011 Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=020262&DrugName=TAXOL&ActiveIngred=PACLITAXEL&SponsorApplicant=HQ%20SPCLT%20PHARMA&ProductMktStatus=1&goto=Search.Label_ApprovalHistory Accessed July 29, 2014
   Google Scholar
• Sanofi U.S.LLC TAXOTERE^® (Docetaxel) Injection Concentrate, Intravenous Infusion (IV) Prescribing Information 2013; USA Bridgewater Sanofi U.S.LLC 2013 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020449s071lbl.pdf Accessed July 29, 2014
   Google Scholar
• Mead Johnson Oncology Products TAXOL^® (Paclitaxel) Injection Princeton Bristol-Meyers Squibb Company 2011 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020262s049lbl.pdf Accessed July 29, 2014
   Google Scholar
• Chien AJ Moasser MM Cellular mechanisms of resistance to anthracyclines and taxanes in cancer: intrinsic and acquired Semin Oncol 2008 35 S1 S14 18410794
   PubMed Web of Science ®Google Scholar
• Fojo AT Menefee M Microtubule targeting agents: basic mechanisms of multidrug resistance (MDR) Semin Oncol 2005 32 S3 S8 16360716
   PubMed Web of Science ®Google Scholar
• Perez EA Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance Mol Cancer Ther 2009 8 2086 2095 19671735
   PubMed Web of Science ®Google Scholar
• O’Neill AJ Prencipe M Dowling C Characterisation and manipulation of docetaxel resistant prostate cancer cell lines Mol Cancer 2011 10 126 21982118
   PubMed Web of Science ®Google Scholar
• Bouchard H Semiond D Risse ML Vrignaud P Novel taxanes: Cabazitaxel case study Fischer J Ganellin CR Rotella DP Analogue-Based Drug Discovery III first edition Weinheim, Germany Wiley-VCH Verlag GmbH & Co. KGaA 2013 13 319 341
   Google Scholar
• de Bono JS Oudard S Ozguroglu M Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Lancet 2010 376 1147 1154 20888992
   PubMed Web of Science ®Google Scholar
• Sanofi JEVTANA^® (Cabazitaxel) Injection, Summary of Product Characteristics Bridgewater Sanofi 2012 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002018/WC500104764.pdf Accessed July 29, 2014
   Google Scholar
• Sanofi U.S.LLC JEVTANA^® (Cabazitaxel) Injection, Prescribing Information, FDA Bridgewater Sanofi U.S.LLC 2013 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201023s003lbl.pdf Accessed July 29, 2014
   Google Scholar
• Jordan MA Mechanism of action of antitumor drugs that interact with microtubules and tubulin Curr Med Chem Anticancer Agents 2002 2 1 17 12678749
   PubMedGoogle Scholar
• Jordan MA Wilson L Microtubules as a target for anticancer drugs Nat Rev Cancer 2004 4 253 265 15057285
   PubMed Web of Science ®Google Scholar
• Nogales E Structural insight into microtubule function Annu Rev Biophys Biomol Struct 2001 30 397 420 11441808
   PubMedGoogle Scholar
• Giannakakou P Poy G Zhan Z Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer Oncogene 2000 19 3078 3085 10871860
   PubMed Web of Science ®Google Scholar
• Kavallaris M Kuo DY Burkhart CA Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes J Clin Invest 1997 100 1282 1293 9276747
   PubMed Web of Science ®Google Scholar
• McGrogan BT Gilmartin B Carney DN McCann A Taxanes, microtubules and chemoresistant breast cancer Biochim Biophys Acta 2008 1785 96 132 18068131
   PubMed Web of Science ®Google Scholar
• Modi S DiGiovanna MP Lu Z Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer Cancer Invest 2005 23 483 487 16203655
   PubMed Web of Science ®Google Scholar
• ABCB1 ATP-binding cassette, sub-family B (MDR/TAP), member 1 [webpage on the Internet] Bethesda NCBI 2014 Available from: http://www.ncbi.nlm.nih.gov/gene/5243
   Google Scholar
• Nightingale G Ryu J Cabazitaxel (jevtana): a novel agent for metastatic castration-resistant prostate cancer P T 2012 37 440 448 23091336
   PubMedGoogle Scholar
• Horwitz SB Cohen D Rao S Ringel I Shen HJ Yang CP Taxol: mechanisms of action and resistance J Natl Cancer Inst Monogr 1993 15 55 61 7912530
   PubMedGoogle Scholar
• Yin S Bhattacharya R Cabral F Human mutations that confer paclitaxel resistance Mol Cancer Ther 2010 9 327 335 20103599
   PubMed Web of Science ®Google Scholar
• Vrignaud P Sémiond D Lejeune P Preclinical antitumor activity of cabazitaxel, a semi-synthetic taxane active in taxane-resistant tumors Clin Cancer Res 2013 19 2973 2983 23589177
   PubMed Web of Science ®Google Scholar
• Lavelle F Bissery MC Combeau C Riou JF Vrignaud P André S Preclinical evaluation of docetaxel (Taxotere) Semin Oncol 1995 22 3 16
   Web of Science ®Google Scholar
• Denis JN Greene AE Guenard D Gueritte-Voegelein F Mangatal L Potier P Highly efficient, practical approach to natural taxol J Am Chem Soc 1988 110 5917 5919
   Web of Science ®Google Scholar
• Holton RA Somoza C Kim H-B First total synthesis of Taxol. 1. Functionalization of the B ring J Am Chem Soc 1994 116 1597 1598
   Web of Science ®Google Scholar
• Sanofi U.S.LLC Taxotere^® Material Safety Data Sheet Bridgewater Sanofi U.S.LLC 2010 Available from: http://bdipharma.com/MSDS/Sanofi-Aventis/Taxotere%208-10.pdf Accessed July 29, 2014
   Google Scholar
• Roche VF Cancer and chemotherapy Lemke TL Williams DA Roche VF Zito SW Foye’s Principles of Medicinal Chemistry seventh edition Baltimore, MD Lippincott Williams, Wilkins 2013 37 1199 1266
   Google Scholar
• Montaudon D Vrignaud P Londos-Gagliardi D Robert J Fluorescence anisotropy of cell membranes of doxorubicin-sensitive and -resistant rodent tumoral cells Cancer Res 1986 46 5602 5605 3756908
   PubMed Web of Science ®Google Scholar
• Azarenko O Smiyun G Mah J Wilson L Jordan MA Antiproliferative mechanism of action of the novel taxane cabazitaxel as compared with the parent compound docetaxel in MCF7 breast cancer cells Mol Cancer Ther 2014 13 2092 2103 24980947
   PubMed Web of Science ®Google Scholar
• Paller CJ Antonarakis ES Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer Drug Des Devel Ther 2011 5 117 124
   PubMed Web of Science ®Google Scholar
• Semiond D Sidhu SS Bissery M-C Vrignaud P Can taxanes provide benefit in patients with CNS tumors and in pediatric patients with tumors? An update on the preclinical development of cabazitaxel Cancer Chemother Pharmacol 2013 72 515 528 23820961
   PubMed Web of Science ®Google Scholar
• Ridoux L Semiond D Vincent C A Phase I open-label study investigating the disposition of [14C]-cabazitaxel in patients with advanced solid tumors Anticancer Drugs Submitted 3 2014
   Web of Science ®Google Scholar
• Darshan MS Loftus MS Thadani-Mulero M Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer Cancer Res 2011 71 6019 6029 21799031
   PubMed Web of Science ®Google Scholar
• Gan L Chen S Wang Y Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer Cancer Res 2009 69 8386 8394 19826044
   PubMed Web of Science ®Google Scholar
• Zhu ML Horbinski CM Garzotto M Qian DZ Beer TM Kyprianou N Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer Cancer Res 2010 70 7992 8002 20807808
   PubMed Web of Science ®Google Scholar
• Bourre L Nicolle D Legrier M-E Evaluation of the response to cabazitaxel of a docetaxel-responsive hormone-refractory prostate tumor xenograft model (HID28) American Society of Clinical Oncology Annual Meeting June 1–5, 2012 Chicago, Illinois Abstract e15161
   Google Scholar
• Chamberlain MC Kormanik P Salvage chemotherapy with paclitaxel for recurrent primary brain tumors J Clin Oncol 1995 13 2066 2071 7636549
   PubMed Web of Science ®Google Scholar
• Chamberlain MC Kormanik P Salvage chemotherapy with taxol for recurrent anaplastic astrocytomas J Neurooncol 1999 43 71 78 10448874
   PubMed Web of Science ®Google Scholar
• Forsyth P Cairncross G Stewart D Goodyear M Wainman N Eisenhauer E Phase II trial of docetaxel in patients with recurrent malignant glioma: a study of the National Cancer Institute of Canada Clinical Trials Group Invest New Drugs 1996 14 203 206 8913841
   PubMed Web of Science ®Google Scholar
• Hurwitz CA Strauss LC Kepner J Paclitaxel for the treatment of progressive or recurrent childhood brain tumors: a pediatric oncology phase II study J Pediatr Hematol Oncol 2001 23 277 281 11464982
   PubMed Web of Science ®Google Scholar
• Prados MD Schold SC Spence AM Phase II study of paclitaxel in patients with recurrent malignant glioma J Clin Oncol 1996 14 2316 2321 8708723
   PubMed Web of Science ®Google Scholar
• Deeken JF Loscher W The blood-brain barrier and cancer: transporters, treatment, and Trojan horses Clin Cancer Res 2007 13 1663 1674 17363519
   PubMed Web of Science ®Google Scholar
• Fellner S Bauer B Miller DS Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo J Clin Invest 2002 110 1309 1318 12417570
   PubMed Web of Science ®Google Scholar
• Kemper EM Verheij M Boogerd W Beijnen JH van Tellingen O Improved penetration of docetaxel into the brain by co-administration of inhibitors of P-glycoprotein Eur J Cancer 2004 40 1269 1274 15110893
   PubMed Web of Science ®Google Scholar
• Cisternino S Bourasset F Archimbaud Y Sémiond D Sanderink G Scherrmann JM Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P-glycoprotein at the blood-brain barrier in mice and rats Br J Pharmacol 2003 138 1367 1375 12711638
   PubMed Web of Science ®Google Scholar
• Izbicka E Campos D Marty J Carrizales G Mangold G Tolcher A Molecular determinants of differential sensitivity to docetaxel and paclitaxel in human pediatric cancer models Anticancer Res 2006 26 1983 1988 16827133
   PubMed Web of Science ®Google Scholar
• Blaney SM Seibel NL O’Brien M Phase I trial of docetaxel administered as a 1-hour infusion in children with refractory solid tumors: a collaborative pediatric branch, National Cancer Institute and Children’s Cancer Group trial J Clin Oncol 1997 15 1538 1543 9193350
   PubMed Web of Science ®Google Scholar
• Hurwitz CA Relling MV Weitman SD Phase I trial of paclitaxel in children with refractory solid tumors: a Pediatric Oncology Group Study J Clin Oncol 1993 11 2324 2329 7902425
   PubMed Web of Science ®Google Scholar
• Mora J Cruz CO Parareda A de Torres C Treatment of relapsed/refractory pediatric sarcomas with gemcitabine and docetaxel J Pediatr Hematol Oncol 2009 31 723 729 19727011
   PubMed Web of Science ®Google Scholar
• Zwerdling T Krailo M Monteleone P Phase II investigation of docetaxel in pediatric patients with recurrent solid tumors: a report from the Children’s Oncology Group Cancer 2006 106 1821 1828 16532433
   PubMed Web of Science ®Google Scholar
• Clinicaltrials.gov [webpage on the Internet] Cabazitaxel in pediatric and central nervous system tumors Bethesda National Institutes of Health 2014 Available from: http://www.clinicaltrials.gov/ct2/show/NCT01751308 Accessed July 29, 2014
   Google Scholar
• Lorch JH Goloubeva O Haddad RI Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial Lancet Oncol 2011 12 153 159 21233014
   PubMed Web of Science ®Google Scholar
• Van Cutsem E Moiseyenko VM Tjulandin S Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group J Clin Oncol 2006 24 4991 4997 17075117
   PubMed Web of Science ®Google Scholar
• Piccart MJ Bertelsen K James K Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results J Natl Cancer Inst 2000 92 699 708 10793106
   PubMed Web of Science ®Google Scholar
• Rosell R Gatzemeier U Betticher DC Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial Ann Oncol 2002 13 1539 1549 12377641
   PubMed Web of Science ®Google Scholar
• Sanofi U.S.LLC TAXOTERE^® (Docetaxel) Injection Concentrate, Intravenous Infusion (IV) Prescribing Information Bridgewater Sanofi U.S.LLC 2010 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020449s059lbl.pdf Accessed May 2014
   Google Scholar
• Vrignaud P Therapeutic synergism of cabazitaxel in combination with cisplatin in tumor-bearing mice American Association for Cancer Research Annual Meeting April 2–6, 2011 Orlando, Florida Abstract 2522
   Google Scholar
• Lockhart AC Sundaram S Sarantopoulos J Phase I trial of cabazitaxel plus cisplatin in patients with advanced solid tumors Poster 162 presented at: Genitourinary Cancers Symposium February 2–4, 2012 San Francisco, California
   Google Scholar
• Rixe O Puzanov I LoRusso PM Dose-escalation Phase I study of cabazitaxel (Cbz) + gemcitabine (Gem) in patients (pts) with metastatic or unresectable advanced solid malignancy Poster 497P presented at: European Society of Medical Oncology Congress Sept 28 – Oct 2, 2012 Vienna
   Google Scholar
• Bissery MC Nohynek G Sanderink GJ Lavelle F Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: Preclinical experience Anticancer Drugs 1995 6 339 8 7670132
   PubMed Web of Science ®Google Scholar
• Rowinsky EK Cazenave LA Donehower RC Taxol: a novel investigational antimicrotubule agent J Natl Cancer Inst 1990 82 1247 1259 1973737
   PubMed Web of Science ®Google Scholar
• Kudoh S Takeda K Nakagawa K Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904) J Clin Oncol 2006 24 3657 3663 16877734
   PubMed Web of Science ®Google Scholar
• Jones SE Erban J Overmoyer B Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer J Clin Oncol 2005 23 5542 5551 16110015
   PubMed Web of Science ®Google Scholar
• Fossella FV DeVore R Kerr RN Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group J Clin Oncol 2000 18 2354 2362 10856094
   PubMed Web of Science ®Google Scholar
• Gradishar WJ Tjulandin S Davidson N Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer J Clin Oncol 2005 23 7794 7803 16172456
   PubMed Web of Science ®Google Scholar
• Miller K Wang M Gralow J Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer N Engl J Med 2007 357 2666 2676 18160686
   PubMed Web of Science ®Google Scholar
• Winer EP Berry DA Woolf S Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342 J Clin Oncol 2004 22 2061 2068 15169793
   PubMed Web of Science ®Google Scholar
• Gokhale PC Newsome JT Dritschilo A Toxicity, histopathologic and pharmacokinetic evaluation of liposome-encapsulated paclitaxel and Taxol in mice and rabbits Poster 2759 presented at: American Association for Cancer Research Annual Meeting April 10–14, 1999 Philadelphia, Pennsylvania
   Google Scholar
• Tinwell H Ashby J Genetic toxicity and potential carcinogenicity of taxol Carcinogenesis 1994 15 1499 1501 7914474
   PubMed Web of Science ®Google Scholar
• Diéras V Lortholary A Laurence V Cabazitaxel in patients with advanced solid tumours: Results of a Phase I and pharmacokinetic study Eur J Cancer 2013 49 25 34 22975213
   PubMed Web of Science ®Google Scholar
• Fumoleau P Trigo JM Isambert N Sémiond D Gupta S Campone M Phase I dose-finding study of cabazitaxel administered weekly in patients with advanced solid tumours BMC Cancer 2013 13 460 24099585
   PubMed Web of Science ®Google Scholar
• Mita AC Denis LJ Rowinsky EK Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors Clin Cancer Res 2009 15 723 730 19147780
   PubMed Web of Science ®Google Scholar
• Pivot X Koralewski P Hidalgo JL A multicenter phase II study of XRP6258 administered as a 1-h iv infusion every 3 weeks in taxane-resistant metastatic breast cancer patients Ann Oncol 2008 19 1547 1552 18436520
   PubMed Web of Science ®Google Scholar
• Villanueva C Awada A Campone M A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I/II study Eur J Cancer 2011 47 1037 1045 21339064
   PubMed Web of Science ®Google Scholar
• Villanueva C Awada A Campone M A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I/II study Eur J Cancer 2011 47 7 1037 1045 21339064
   PubMed Web of Science ®Google Scholar
• Ferron GM Dai Y Semiond D Population pharmacokinetics of cabazitaxel in patients with advanced solid tumors Cancer Chemother Pharmacol 2013 71 681 692 23299792
   PubMed Web of Science ®Google Scholar
• Bruno R Vivier N Vergniol JC De Phillips SL Montay G Sheiner LB A population pharmacokinetic model for docetaxel (Taxotere): model building and validation J Pharmacokinet Biopharm 1996 24 153 172 8875345
   PubMedGoogle Scholar
• Clarke SJ Rivory LP Clinical pharmacokinetics of docetaxel Clin Pharmacokinet 1999 36 99 114 10092957
   PubMed Web of Science ®Google Scholar
• Smith TJ Khatcheressian J Lyman GH 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline J Clin Oncol 2006 24 3187 3205 16682719
   PubMed Web of Science ®Google Scholar
• Malik Z Di Lorenzo G Ardavanis A Updated safety results from a cohort compassionate-use programme (CUP) and early access programme (EAP) with cabazitaxel (Cbz) plus prednisone (P; Cbz + P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D) Eur J Cancer 2013 49 Supplement 2 S1 S1028 abstract 2902
   Google Scholar